^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CYP11A1 inhibitor

    Related drugs:
    15d
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1314, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    22d
    Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2028 --> Jan 2029 | Trial primary completion date: Mar 2028 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    Lynparza (olaparib) • docetaxel • prednisone • cabazitaxel • opevesostat (MK-5684)
    1m
    A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010) (clinicaltrials.gov)
    P1, N=24, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    prednisone • opevesostat (MK-5684)
    2ms
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1314, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Dec 2030 --> May 2028
    Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    2ms
    A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010) (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    prednisone • opevesostat (MK-5684)
    2ms
    OMAHA1: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1310, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    3ms
    A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jan 2026 --> Apr 2026 | Trial primary completion date: Jan 2026 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    opevesostat (MK-5684)
    3ms
    A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=84, Recruiting, Shenzhen Ionova Life Sciences Co., Ltd. | Phase classification: P1 --> P1/2 | Trial completion date: Mar 2027 --> Jan 2028
    Phase classification • Trial completion date
    3ms
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1500, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    4ms
    A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (clinicaltrials.gov)
    P2, N=250, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | Trial completion date: Jul 2030 --> Nov 2027 | Trial primary completion date: Jul 2030 --> Nov 2027
    Enrollment open • Trial completion date • Trial primary completion date • Pan tumor
    |
    tamoxifen • fulvestrant • letrozole • exemestane • megestrol • opevesostat (MK-5684)
    4ms
    CYPIDES: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=204, Active, not recruiting, Orion Corporation, Orion Pharma | Trial completion date: Jun 2025 --> Jul 2026 | Trial primary completion date: Jun 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    opevesostat (MK-5684) • midazolam hydrochloride
    5ms
    OMAHA1: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)